2019 CYIR Finalized
22 MYCOBACTERIAL INFECTIONS David J. Horne, MD, MPH Harborview Medical Center, University of Washington Division of Pulmonary, Critical Care, and Sleep Medicine Seattle, WA MONDAY, MAY 20 MYCOBACTERIAL INFECTIONS TREATMENT OF LATENT TB INFECTION Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Obeng Baah J, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata RC, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion M-J, Li P-Z, Hill PC, Schwartzman K, Benedetti A. Four months of rifampin or nine months of isoniazid for latent tubercu- losis in adults. N Engl J Med 2018; 379:440-53. Summary Although 4 months of daily rifampin (4R) has been a guide- line recommended treatment for latent TB infection (LTBI), this regimen had not been studied in randomized trials. To evaluate the efficacy and safety of rifampin for the treat- ment of LTBI, investigators completed a phase 3 trial of 4 months of daily rifampin compared to 9 months of daily isoniazid for the prevention of TB disease. This random- ized open-label trial enrolled adults from study sites in Canada, Brazil, West Africa, Asia, and Australia who were tuberculin skin test or interferon-gamma release assay (IGRA)-positive, and at increased risk for progression to TB disease. Participants were followed for 28 months after randomization to compare rates of TB, adverse events, and completion of treatment (defined as > 80% of doses). The study enrolled >6000 participants from 2009 to 2014 and included 614 participants previously enrolled in a phase 2 safety study. There were >6800 participants in the modified intention-to-treat analysis, and confirmed TB was diag- nosed in 8 participants (4 in each arm). Rifampin was non- inferior to isoniazid for TB prevention. Completion rates in the rifampin arm were higher (79%) than the isoniazid arm (63%). The rate of grades 3-5 adverse events was lower in the rifampin arm, including drug-induced hepatitis. Comments 1. This study, together with an accompanying trial of 4R in chil- dren, demonstrates that rifampin is safer and more likely to be completed than isoniazid, with similar efficacy in preventing TB. 2. Two shorter rifamycin-based regimens, 4 months of rifampin or 3 months of weekly rifapentine/isoniazid, should be the pre- ferred regimens for TB prevention as they are safer and more likely to be completed than isoniazid. 3. The superior safety profiles of rifamycin-based regimens should be grounds for expanding the screening and treatment of LTBI in the U.S., as this is key to TB elimination. 4. There has been resistance in high burden settings to the use of rifampin for TB prevention due to concerns of treating patients with unrecognized TB disease with a single agent, and it is unclear if there will be widespread uptake of 4R in these set- tings. TUBERCULOSIS VACCINE Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, Ayles HM, Henostroza G, Thienemann F, Scriba TJ, Diacon A, Blatner GL, Demoitie MA, Tameris M, Malahleha M, Innes JC, Hellstrom E, Martinson N, Singh T, Akite EJ, Khatoon Azam A, Bollaerts A, Ginsberg AM, Evans TG, Gillard P, Tait DR. Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med. 2018;379(17):1621-34. Summary An effective vaccine against TB is urgently needed. The M72/AS01E candidate vaccine (M72) contains the M72 recombinant fusion protein derived from 2 immunogenic M. tuberculosis antigens combined with the AS01 adjuvant system. This study reports the results of a primary analysis of a phase 2b trial of M72 efficacy in preventing TB disease that was funded by GSK and Aeras. This double-blind, randomized, placebo-controlled trial enrolled HIV-negative, IGRA-positive adults (18 – 50 years) from 3 countries, Kenya, Zambia, and South Africa, and randomized participants to 2 intravascular doses of M72 or placebo. 3283 participants were included in the per-protocol efficacy analysis, among whom the mean age was 29 years and 81% were enrolled in South Africa. A total of 32 cases of TB disease were diagnosed, 10 in the M72 arm and 22 in the placebo arm, over a mean follow-up time of 2.3 years. Overall M72 effi- cacy was 54% (95% CI=3-79%). Prespecified sub-group analyses suggested greater efficacy in participants < 25 years of age (84% efficacy compared to 10% in >25 years) and men (75% efficacy compared to 27% in women). The occurrence of serious adverse events was similar in both groups.
Made with FlippingBook
RkJQdWJsaXNoZXIy MTM1ODMw